Background/Aim: Cystatin C (Cys C) is an endogenous marker of glomerular filtration rate (GFR) unaffected by body composition. The aim of the present study was to assess the utility of Cys C-based GFR prediction equations (Hoek, Larsson and Stevens) and creatinine (modification of diet in renal disease-isotope dilution mass spectrometry – MDRD-IDMS, and Cockcroft-Gault – CG) compared with 51Cr-EDTA. Methods: This study was carried out in 40 Caucasian older patients with advanced age (≥60) and chronic kidney disease stages 3–4. To assess the utility of prediction equations in relation to body composition, we measured lean mass (LM) with densitometry (DXA). Pearson’s, Bland-Altman and Lin’s coefficient (Rc) were used to study accuracy and precision. Results:51Cr-EDTA was 36.9 ± 9.2 ml/min/1.73 m2 (22–60). Cys C levels were 2.2 ± 0.8 mg/l (r = 0.085; p = 0.662 LM) and creatinine 2.8 ± 1.1 mg/dl (r = 0.427; p = 0.021 LM). The most accurate equations were the Hoek, Larsson and Stevens formulae, with a bias of –0.2 (Rc 0.48), –2.9 (Rc 0.44) and 2.6 ml/min/1.73 m2 (Rc 0.58). The biases obtained with MDRD-IDMS and CG were –14.6 (Rc 0.35) and –12.5 (Rc 0.40). All correlations among biases obtained with creatinine-based formulae and LM were negative and statistically significant (p < 0.05). Conclusions: The results show superiority of Cys C-based GFR formulae over the MDRD-IDMS and CG equations. This significant underestimation obtained with conventional prediction equations was directly related to the influence of LM.

1.
Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB: Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003;41:1364–1372.
2.
European Best Practice Guidelines Expert Group on Hemodialysis: Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002;17(suppl 7):7–15.
3.
US Renal Data System: USRDS 1999 Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2001.
4.
Fontseré N, Bonal J, Navarro M, Riba J, Fraile M, Torres F, Romero R: A comparison of prediction equations for estimating glomerular filtration rate in adult patients with chronic kidney disease stages 4–5. Effect of nutritional status and age. Nephron Clin Pract 2006;104:c160–c168.
5.
Vinge E, Lindergard B, Nilsson-Ehle P, Grubb A: Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults. Scand J Clin Lab Invest 1999;59:587–592.
6.
Chumlea WC: Anthropometric and body composition assessment in dialysis patients. Semin Dial 2004;17:466–470.
7.
Fresco GF, DiGiorgio F, Curti GL: Simultaneous estimation of glomerular filtration rate and renal plasma flow. J Nucl Med 1995;36:1701–1706.
8.
Hoek FJ, Kemperman FA, Krediet RT: A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003;18:2024–2031.
9.
Larsson A, Malm J, Grubb A, Hansson LO: Calculation of glomerular filtration rate expressed in ml/min from plasma cystatin C values in mg/l. Scand J Clin Lab Invest 2004;64:25–30.
10.
Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395–406.
11.
Levey AS, Coresh J, Greene J: [F-Fc 142]. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold-standard). http://nkdep.nih.gov/labprofes-sionals/F_Fc142.pdf.
12.
Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
13.
Bland JM, Altman DG: Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135–160.
14.
Lin LI: A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255–268.
15.
Department of Public Health: Catalonia Registry. Barcelona, 2004. http://www.ocatt.net.
16.
Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.
17.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
18.
Fliser D, Ritz E: Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001;37:79–83.
19.
Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221–226.
20.
Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699–707.
21.
Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, Barron J, Lemmey A: GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006;48:712–719.
22.
Rigalleau V, Raffaitin C, Gin H, Beauvieux MC, Le Moigne F, Lasseur C, Chauveau P, Combe C, Barthe N: Accounting for body composition does not improve cystatin C estimation of GFR in diabetic subjects with CKD. Am J Kidney Dis 2006;49:560.
23.
van Rossum LK, Zietse R, Vulto AG, de Rijke YB: Renal extraction of cystatin C versus 125I-iothalamate in hypertensive patients. Nephrol Dial Transplant 2006;21:1253–1256.
24.
Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006;17:254–261.
25.
Wang Z, St-Onge MP, Lecumberri B, Pi- Sunyer FX, Heshka S, Wang J, Kotler DP, Gallagher D, Wielopolski L, Pierson RN Jr, Heymsfield SB: Body cell mass: model development and validation at the cellular level of body composition. Am J Physiol Endocrinol Metab 2004;286:E123–E128.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.